In 2026, Bio-analytical and Toxicology services remain the highest-revenue segments, accounting for over 45% of total market spend. According to US Preclinical CRO Market data, there is a surge in demand for "Immunotoxicology"—testing how new drugs interact with the human immune system, which is critical for the success of immunotherapy and oncology drugs.

The Pharmacokinetics (PK) and Pharmacodynamics (PD) segment is also seeing innovation through "Micro-Sampling" technology. This allows CROs to collect high-quality data from tiny samples, improving the accuracy of data in pediatric and rare disease drug development. Furthermore, the rise of Digital Pathology—using AI to scan and analyze tissue slides—has turned a traditionally slow manual process into an automated, high-precision service that can be reviewed remotely by sponsors across the globe.

FAQ:

• Question: Which service segment is the largest?

• Answer: Toxicology and Bio-analytical services continue to hold the largest market share.

• Question: What is Digital Pathology?

• Answer: The use of AI and high-resolution imaging to automate the analysis of tissue samples, increasing speed and reducing human error.